[Effect of different doses of clofibrate on neonatal jaundice]

Present study was performed to assess effect of diferent dose of clofibrate on neonatal jaundice. In a controlled randomized clinical trial, 132 neonates who admitted in the neonatal ward of Beasat hospital of Hamedan city with diagnosis of non-hemolytic indirect hyperbilirubinemia during a 9 months period [winter 87 till spring 88] were classified completely random in 3 groups: In the first group [control] only phototherapy was done as therapeutic management, in the second group [sample group 1], low dose oral clofibrate [25 mg/kg] and phototherapy was prescribed, and in third group [sample group 2] moderate dose oral clofibrate [50 mg/kg] and phototherapy was prescribed. In all 3 groups, total and indirect bilirubin level was measured at the beginning of therapy and then 12, 24, 36 and 48 hours after therapeutic management. All neonates were visited in outpatient clinic 2 days after discharge. Data was analyzed with SPSS software version 17. There was no significant difference in age, sex, and mean total bilirubin of referred patients of studied groups [P>0.05]. 12, 24 and 36 hours after starting therapy, mean total bilirubin was significantly lower in sample group 1 and 2 than control group [P<0.05], but no significant difference was seen between two sample groups 1 and 2 [P >0.05]. Mean total bilirubin was significantly lower in group 1 and 2 than control group [P= 0.004 and P = 0.001 respectively], but no significant difference was seen between sample group 1 and 2 [P= 0.524]. Mean admission duration and phototherapy duration was significantly lower than control [P<0.05], but there was no significant difference between sample group 1 and 2 [P<0.05]. There was not any report about side effects of clofibrate consumption. Because there was no difference prescribing low or moderate dose of oral clofibrate in lowering bilirubin level and also decreasing phototherapy and admission duration it is suggested to use lower doses of drug for preventing possible complications

Kassabach-merrit syndrome in a newborn: a case report

Kassabach-Merrit syndrome is a consumption coagulopathy that occurs as a complication of angiomatous nevi. The neonate reported here was born without complication and with a good APGAR score. He had petechiae and purpura on the trunk, thighs and shoulders. Gradually, he developed anemia and thrombocytopenia. Serologic tests and cultures were negative for infectious disease. The subcutaneously located patches and nodules increased gradually in size. Biopsy of one of the lesions was consistent with hemangioma of the capillary type. He was treated as a case of consumption coagulopathy associated with cutaneous hemangiomas